Telomeres and telomerase in paediatric patients with T-cell acute lymphoblastic leukaemia (T-ALL)
Telomeres the repetitive DNA sequences at the ends of chromosomes consist of 5-15 kb pairs of multiple copies of TTAGGG sequences. Owing to the so-called 'end replication problem', telomeres shorten with each cell division by 50-200 bp. 1 At a critical telomere length, cells enter senescence or apoptosis. Cells can get immortal by stabilizing the length of their telomeres by activation of the multisubunit enzyme telomerase. In about 85% of all human tumours telomerase activity (TA) has been detected, whereas TA is absent in most normal cells. 2 The presence of TA is limited by the expression of the catalytic subunit of telomerase hTERT (human telomerase reverse transcriptase). 1 It has been shown that TA is a prognostic marker in some solid tumours as well as in haematologic neoplasias. 2 In contrast to solid tumours, few studies exist in haematologic neoplasias regarding TA and telomere length.
Acute lymphoblastic leukaemia (ALL) is the most frequently diagnosed malignancy in childhood and is responsible for more than 80% of childhood leukaemias, whereas the T-cell phenotype accounts for about 10% of diagnosed children with ALL. So far a few reports have been published in terms of telomere length and/or TA in paediatric leukaemic malignancies; [3] [4] [5] [6] [7] [8] [9] however, systematic analyses about TA and telomere length in paediatric patients with T-ALL are still missing.
Although prognosis of T-ALL in childhood has improved with modern chemotherapy, T-ALL patients with failure of inducing a remission or after first relapse still have a very poor prognosis. 10 It is anticipated that new biochemical information might contribute to better therapeutic strategies. In order to investigate the prognostic significance of telomere length, TA and expression of hTERT in paediatric patients with T-ALL, we analysed in an exploratory study these putative biological markers in leukaemic cells from 20 patients (age range 2-17.5 years; mean age 9 years). As not sufficient cell material was available from all 20 patients, interest was focused on telomerase.
Mononuclear cells of leukaemic samples were derived from 20 patients with T-ALL. Patients were enrolled in four consecutive multicenter trials of the Berlin-Frankfurt-Münster group (ALL-BFM 86, 90, 95 and 2000). According to the protocol guidelines, 14 of the patients were treated in the high risk (HR) arm and six patients in the intermediate risk (MR) arm. Prognosis (MR vs HR) and clinical outcome (treatment-induced remission vs relapse or death of disease) were assessed from the individual data of the patients.
Telomere length of samples was determined by telomere restriction fragment (TRF) Southern blot analysis, as previously reported. 11 Leukocytes from 19 children and adolescents (range: 3-17 years; mean age: 10 years) hospitalized for nonmalignant surgical procedures served as controls. TRF in seven of these controls has been reported recently. 11 We found that TRF varied widely (3.5-8.1 kb; mean7s.d.: 6.471.3 kb) in leukaemic cells and it was significantly shorter (Po0.0001, Mann-Whitney test) than that of age-matched controls (8.370.4 kb). Our observation was concordant with previous studies reporting reduction in telomere length in children with acute leukaemia. 3, 4, 8 According to the telomere hypothesis, shortened telomeres are the result of high numbers of population doublings. Thus, telomere length represents a marker for cell proliferation. Consequently, the observed shortened telomeres in the investigated leukaemic samples may reflect a fraction of extensively proliferating cells.
TA was measured using the radioactive telomerase repeat amplification protocol (TRAP) assay. Up to 0.3 mg of total protein extract were used for each assay. Phytohaemagglutinin (PHA) activated and nonactivated peripheral blood mononuclear cells (PBMCs) from a healthy young adult were used for estimation of TA of leukaemic cells. TA of patients' samples, nonactivated PBMCs and PHA stimulated PBMCs was characterized by a semiquantitative score
based on the visual comparison of the telomerase ladder. TA was present in 95% of the leukaemic cells tested. In comparison to nonstimulated and PHA stimulated PBMCs exhibiting weak (score 1) and high TA (score 3), respectively, leukaemic samples demonstrated a large variability in TA (see Table 1 , Figure 1) . In comparison to nonstimulated Figure 1 TRAP gel assay of leukaemic samples and controls. The radioactive TRAP assay (up to 0.3 mg protein, 31 cycles) was used to analyse telomerase activities in specimens obtained from paediatric patients with T-ALL. Telomerase-positive samples are identified by the typical telomerase ladder. Controls: C (nonstimulated PBMCs), C þ (phytohaemagglutinin stimulated PBMCs). PBMCs, we observed elevated levels of TA in leukaemic cells of paediatric patients with T-ALL. Our findings are consistent with previous reports, which showed high levels of TA in samples of children with acute leukaemia compared to healthy individuals. 4, 6, 8 Normalized expression of hTERT was measured at the mRNA level by real-time TaqMan s PCR as described recently.
11 Nonactivated PBMCs obtained from a second healthy young adult served as control. Expression of hTERT demonstrated a large interindividual variability (range 141-424 000 normalized units, see Table 1 ). In nonstimulated PBMCs weak expression of hTERT (1420 normalized units) was measured. All telomerase positive samples expressed hTERT and the patient with undetectable TA (no. 16) demonstrated the lowest expression of hTERT. Although no significant association between both parameters could be observed, our observations could be in favour of such a general relationship between both biochemical markers. Our results are in agreement with previous reports, which showed a general association between TA and expression of hTERT in samples of children with acute leukaemia. 6, 8 Any discordance between expression of hTERT and TA (as seen best in patient no. 11) might be most likely explained by transcriptional regulation of hTERT. 2 In patients with T-ALL TRF, TA and expression of hTERT were not affected by age, sex, cell origin or amount of blasts. Moreover, TRF was independent of TA, but we observed an inverse linear correlation between TRF and hTERT expression (r ¼ À0.574, P ¼ 0.032, Spearman test). However, the impact of this association becomes less impressive as the statistical significance is based solely on the hTERT-and TRF-values of patient no. 7. When the statistical analysis was performed, excluding this patient, the correlation was no longer significant. With respect to clinical features TRF, TA and expression of hTERT were not associated with clinical outcome (remission vs relapse or death of disease) or the initially assessed prognosis (MR vs HR). Thus, our results suggest that TA, expression of hTERT and TRF are not suitable markers for predicting outcome of the patients.
Previously, several investigators have determined TA in paediatric patients with acute leukaemia. Verstovsek et al 7 reported that elevated TA is a prognostic factor for shortened survival in patients with acute myeloid leukaemia (AML). Three studies investigated TA during the course of disease and correlations between enzyme activity and response to therapy were found. [4] [5] [6] Likewise, a reduction of telomere length could be observed during treatment. 4, 5 Our results indicate that longitudinal analysis of TA and TRF in long-term studies would be needed to investigate the impact of changes in TA and telomere length during course of disease and its treatment in children with T-ALL. We are aware that our results are based on a relative small number of patients and that interpretation of the results might be therefore somewhat limited. However, since T-ALL represents the rare subtype of paediatric ALL most studies have to be performed in small groups of patients as recently shown. 12 In summary, we investigated in an exploratory study TRF, TA and expression of hTERT in leukaemic cells of paediatric patients with T-ALL and could not observe significant relationships between these biological parameters and clinical outcome or prognosis. Further controlled long-term studies with larger populations are probably needed to elucidate the clinical value of these biochemical markers for monitoring the course of paediatric T-ALL.
